

Remarks

In the Office Action dated February 22, 2006, the Examiner required restriction to one of the following groups of claims under 35 U.S.C. § 121:

Group I: Claims 1-2, 8-17 drawn to a method for reducing tumor burden, classified in class 514, subclass 2+.

Group II. Claims 3-4, drawn to a method for inhibiting recurrence of gross cystic disease of the breast, classified in class 514, subclass 2+.

Group III. Claims 5-7, drawn to a method for preventing or deducing the frequency or severity of transient ischemic attacks or strokes, classified in class 514, subclass 2+.

Applicant submits that restriction is not necessary in the current instance, and that no undue burden would be placed on the Patent and Trademark Office in searching Groups I-III. Nevertheless, in the interest of furthering prosecution, Applicant hereby elects Group I, Claims 1-2, 8-17, with traverse. In response to the requirement under 35 USC §121 to elect a single disclosed species, Applicant elects species ABX-EGF, as described on page 15, lines 6-9 of Applicant's specification. Claims 1, and 8-10, 12-13, and 15-16 encompass the elected species.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 01-0519.

Respectfully submitted,



Scott N. Bernstein
Attorney for Applicants
Registration No.: 38,827
Phone: (805) 447-4128
Date: May 23, 2006

Please send all future correspondence to:

37582

US Patent Operations/ SNB
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799